Shanghai, China – 20 Sep 2026 – The Shanghai Medical Insurance Centralized Bidding and Procurement Administration Office announced that, pursuant to relevant directives of the National Healthcare Security Administration, the procurement qualification of one drug product – Ganmao Qingre Tablets (film‑coated), manufactured by Hebei Tangwei Pharmaceutical Co., Ltd. – will be suspended from 00:00 on 21 September 2026. The notice was addressed to all medical institutions and drug manufacturers participating in the city’s centralized procurement platform.
Policy Snapshot
| Item | Detail |
|---|---|
| Agency | Shanghai Medical Insurance Centralized Bidding and Procurement Administration Office |
| Authority | Relevant document(s) of the National Healthcare Security Administration (specific document reference not disclosed) |
| Measure | Suspension of procurement qualification |
| Product Affected | 1 – Ganmao Qingre Tablets (film‑coated) |
| Manufacturer | Hebei Tangwei Pharmaceutical Co., Ltd. |
| Effective Time | 00:00, 21 Sep 2026 |
| Suspension Duration | Not disclosed |
| Reason for Suspension | Not disclosed in the notice body |
| Notice Date | 20 Sep 2026 |
Product Under Suspension
| Generic Name | Dosage Form | Specification | Unit | Manufacturer |
|---|---|---|---|---|
| Ganmao Qingre Tablets (traditional Chinese medicine cold‑relief formula) | Film‑coated tablet | 0.55 g per tablet × 32 tablets/box, aluminum‑plastic blister packaging | Box | Hebei Tangwei Pharmaceutical Co., Ltd. |
Compliance Notes
- Scope of Impact: With procurement qualification suspended, the affected Ganmao Qingre Tablets SKU cannot be purchased through Shanghai’s centralized procurement platform by medical institutions from the effective time – though the notice does not specify whether existing contracts or in‑transit orders are affected.
- National‑Level Origin: The suspension is executed on the basis of a national directive rather than a Shanghai‑initiated review, indicating the underlying compliance issue originated at the National Healthcare Security Administration level and may extend to other provinces as they implement the same document.
- Manufacturer Exposure: For Hebei Tangwei Pharmaceutical, the loss of procurement eligibility in Shanghai – one of China’s highest‑value pharmaceutical markets – removes a key public‑channel revenue line for the product until qualification is restored.
- Restoration Pathway: The notice does not disclose the suspension’s duration, the specific grounds, or the procedure for reinstatement; affected enterprises will need to engage with the issuing authorities for remediation and restoration requirements.
Market Impact & Outlook
- Enforcement Signal: The swift, midnight‑effective implementation underscores the increasingly automated and directive‑driven nature of China’s drug procurement credit management, where national‑level determinations translate directly into provincial platform actions.
- TCM Procurement Discipline: The targeted product is a traditional Chinese medicine cold‑relief formula, extending procurement‑compliance enforcement into the TCM segment alongside chemical drugs and biologics.
- Cross‑Province Watch: Because the action stems from a national directive, distributors and manufacturers should monitor whether other provincial procurement platforms issue matching suspension notices for the same product – a common pattern under China’s nationwide price‑and‑credit linkage mechanisms.
- Immediate Action for Medical Institutions: Shanghai hospitals and clinics should remove the suspended SKU from ordering workflows effective 21 September to avoid transaction failures and compliance exposure.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the suspension of procurement qualification, potential restoration of trading eligibility, and related enforcement actions for Ganmao Qingre Tablets in Shanghai and other jurisdictions. Actual results may differ due to risks including undisclosed suspension grounds and duration, appeal or remediation outcomes, and subsequent policy actions by the National Healthcare Security Administration and the Shanghai Medical Insurance Centralized Bidding and Procurement Administration Office.-China Health Reform Pulse
Policy Source: https://www.smpaa.cn/xxgk/gggs/2026/09/20/24901.shtml